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Abstract
The prolonged mechanical ventilation that is often required by patients with severe COVID-19 is expected to result in signifi-
cant intensive care unit-acquired weakness (ICUAW) in many of the survivors. However, in our post-COVID-19 follow-up 
clinic we have found that, as well as the anticipated global weakness related to loss of muscle mass, a significant proportion 
of these patients also have disabling focal neurological deficits relating to multiple axonal mononeuropathies. Amongst the 
69 patients with severe COVID-19 that have been discharged from the intensive care units in our hospital, we have seen 11 
individuals (16%) with such a mononeuritis multiplex. In many instances, the multi-focal nature of the weakness in these 
patients was initially unrecognised as symptoms were wrongly assumed to relate simply to “critical illness neuromyopathy”. 
While mononeuropathy is well recognised as an occasional complication of intensive care, our experience suggests that such 
deficits are surprisingly frequent and often disabling in patients recovering from severe COVID-19.
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Introduction and case series
The respiratory manifestations of the COVID-19 pandemic 
have strained health-care systems around the world [1]. 
Thousands of patients have required prolonged periods of 
mechanical ventilation and many are inevitably emerging 
with significant “intensive care unit-acquired weakness” 
(ICUAW) [2, 3]. Amongst the COVID-19 survivors attend-
ing our ICU follow-up clinic we have noticed that, in addi-
tion to the anticipated symmetrical weakness related to 
sarcopaenia [4], a significant number of these patients also 
have marked focal neurological deficits related to super-
imposed mononeuropathies. Here we present the findings 
in the first 11 such patients that we have seen (Fig. 1 and 
Table 1), many of whom are significantly disabled by their 
neuropathies.
All these patients had severe COVID-19 necessitating 
mechanical ventilation for an average of 36 days (range 
16–73), five required periods of prone positioning, and one 
required extra-corporeal membrane oxygenation (ECMO). 
Eight of the 11 were men (representative of the known 
sex difference for severe disease), and the median age was 
58 years (range 50–77). Four of the patients had type 2 dia-
betes (none on insulin) and most were overweight, the mean 
baseline BMI being 28 (range 21–53). The neuropathies 
were noted following withdrawal of sedation, indicating that 
these nerve injuries developed during the period of ventila-
tion. The clinical deficits have been static or improving when 
reviewed serially during convalescence, suggesting that the 
active disease process was limited to the acute phase. In 
several of the patients, the neuropathies substantially pro-
longed the need for inpatient rehabilitation and delayed hos-
pital discharge.
All of the patients had evidence of a modest global sym-
metrical weakness consistent with the sarcopaenia that 
would be expected following severe critical illness, but 
none showed electomyographic (EMG) evidence of myo-
pathy. Similarly, only one of the patients showed evidence of 
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concomitant generalised neuropathy (potentially reflecting 
“critical illness neuropathy” [2]), and this was only mild 
electrophysiologically. Considering conduction velocity, 
distal latency, compound muscle action potential (CMAP) 
duration and F-wave latency, and applying the European 
Federation of Neurological Societies criteria [5] (originally 
developed for chronic inflammatory demyelinating polyra-
diculoneuropathy), we found no evidence of demyelination 
in any of the affected nerves, with the possible exception of 
modest conduction block (< 50%) in the right median nerve 
of one patient. In contrast, all of the patients showed evi-
dence of focal axonal loss with denervation in relevant mus-
cles on EMG and corresponding reductions in both CMAP 
and sensory nerve action potential (SNAP) amplitudes on 
nerve conduction testing. Amplitude was reduced to less 
than 50% of normal and/or less than 50% of the amplitude 
on the contralateral side in at least one nerve in each patient. 
Clinically and electrophysiologically, nerve involvement was 
often patchy, with some nerve fascicles being more severely 
affected than others. In those patients with partial sciatic 
neuropathies, it was notable that extensor hallucis longus 
was invariably the most severely affected muscle, out of 
proportion to the weakness in tibialis anterior and peroneus 
longus. Ultrasound scanning of affected nerves was under-
taken in three patients and demonstrated diffuse thickening 
of the affected nerves. The one patient with bilateral femoral 
neuropathies was found to have bilateral psoas haematomata 
(a recognised complication of ECMO) on MRI; however, 
the lower parts of the lumbosacral plexus were uninvolved 
confirming that these haematomas were not responsible for 
his sciatica nerve deficits (and obviously did not explain his 
upper limb neuropathies). Lumbosacral plexus MRI, per-
formed in a second patient with bilateral profound sciatic 
nerve lesions, was unremarkable: no alternate compressive 
lesions were identified, and the nerves within the plexus 
appeared normal. MRI of the brachial plexus in a third 
patient was also unremarkable; the nerves appeared normal 
with no evidence of direct injury or avulsion, and no alterna-
tive compressive cause identified. As no patient displayed 
progressive disease, neither nerve biopsy nor lumbar punc-
ture wasundertaken. In the acute phase of their illness, all 
patients had raised CRP (median 350 [range 268–523]; ref-
erence range 0–6), interleukin-6 (median 28.9 pg/ml [range 
3.4–400]; reference range 0-2 pg/ml), and d-dimer (median 
1059 ng/ml [range 348–14135]; reference range 0-230 ng/
ml), but the spectrum of elevation was broad.
At the time of writing, 102 COVID-19-positive patients 
have been treated in the ICUs in our hospital, 44 of these 
have been discharged home, 14 have been transferred to 
other hospitals for further rehabilitation, 11 are still recover-
ing in our hospital and 33 have died. Not all of the discharged 
patients have yet been seen for follow-up so additional cases 
of mononeuropathy may still come to light. Whilst monon-
europathies are a well-recognised complication of anaesthe-
sia and intensive care [2], the number of affected patients (at 
least 16% of those discharged from ICU in our hospital), the 
number of nerves affected in each patient (an average of just 
over 3 per patient), and the particular nerves involved (such 
as the proximal sciatic) are all outside common experience. 
There have been previous descriptions of bilateral sciatic 
neuropathies resulting from intensive care, with the patient 
initially being mistakenly thought to have critical illness 
neuropathy, but such patients are sufficiently uncommon to 
warrant individual case reports [6].
Discussion
This series of cases highlights an important neurological 
complication occurring frequently in patients with severe 
COVID-19, which detrimentally affects long-term outcomes 
and markedly influences their rehabilitation needs. Given 
that, this complication is evident in a significant proportion 
of the patients discharged from the intensive care units of a 
single hospital (16% in our cohort of treated patients) and 
the rehabilitation burden globally could be substantial. Fur-
thermore, given the high expectation of ICUAW, these focal 
deficits may go unnoticed.
The underlying aetiology of these neuropathies remains 
to be established. Mechanical factors related to patient 
handling and positioning are recognised to occasionally 
cause focal neuropathy [7], raising the possibility that per-
haps patients with severe COVID-19 are very much more 
susceptible to such nerve injuries. Against this, we saw 
no evidence for the demyelinating features typically seen 
in such injuries, and many of our patients had neuropa-
thies at sites that would be highly unusual for compres-
sion or traction (including musculocutaneous, proximal 
median and high sciatic neuropathies). From a clinical 
and electrophysiological perspective, the neurological 
deficits we have seen in our patients have much in com-
mon with vasculitic neuropathies such as lumbosacral 
radiculoplexus neuropathy (Bruns–Garland syndrome) 
and brachial neuritis (Parsonage–Turner syndrome) [8]. 
However, these syndromes are usually, but not always, 
proceeded by considerable pain, which was not a com-
mon feature in our cohort. However, since our patients 
developed their deficits while they were sedated and ven-
tilated, this phase of the illness was necessarily obscured. 
Fig. 1  Schematic homuncular illustration of the sensory and motor 
deficits arising from the multiple mononeuropathies present in 11 
patients recovering from severe COVID-19. Hatched shading indi-
cates posterior muscle groups (hamstrings and triceps). In those neu-
ropathies listed as sciatic, there was involvement of both common 
peroneal and tibial divisions
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Furthermore, post-mortem studies have confirmed that 
vasculitis is prominent in a range of tissues in patients 
dying from COVID-19, although peripheral nerve tissue 
has not yet been specifically examined [9]. The aetiology 
of this vasculitis is also uncertain, but might relate to an 
endotheliopathy [10] resulting from the “cytokine storm” 
that is so characteristic of these patients [11], or perhaps 
the microthrombi [12] that are known to frequently occur 
in COVID-19. The elevations of Interleukin 6 and d-dimer 
seen in these patients are in keeping with these respective 
processes, but the broad ranges seen do not clearly support 
one above the other.
In summary, we have observed a mononeuritis mul-
tiplex in a significant fraction of the patients with serve 
COVID-19 that were admitted to the intensive care units 
of our hospital. While we recognise this is a small number 
of individuals in total, and that we have no direct compara-
tive group to demonstrate that this phenomenon is unique 
to COVID-19, the clinical features are striking and their 
implications for rehabilitation profound. We strongly urge 
detailed neurological assessment of patients with post-
COVID-19 ICUAW, especially those with asymmetric 
weakness, as we suspect that many such patient are likely 
to have focal deficits.
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